Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA crosslinking refers to the formation of covalent bonds between two nucleotides within DNA, either on the same strand (intrastrand) or between opposite strands (interstrand). This process can be triggered by various exogenous agents (such as chemotherapeutic drugs, radiation, or environmental toxins) or endogenous factors. Crosslinks disrupt essential cellular processes such as replication and transcription, leading to cell death. It is a key target in cancer therapy using crosslinking agents that induce apoptosis in rapidly dividing cells. Cells have evolved complex repair pathways for resolving these lesions involving NER, homologous recombination, and base excision repair pathways.
Drugs like cisplatin and nitrogen mustards introduce covalent crosslinks between DNA strands, particularly at guanine residues, which disrupts DNA replication and transcription, leading to cell cycle arrest and apoptosis, especially in rapidly dividing cells such as cancer cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (Crosslinking) (DNA Crosslinking).